Shopping Cart 0
Cart Subtotal
USD 0

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Pipeline Review, H1 2017

Summary

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Calcitonin Gene Related Peptide Type 1 Receptor-Pipeline Review, H1 2017, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 6 and 3 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Undisclosed which include indications Migraine, Inflammatory Pain, Dental Pain, Diabetic Neuropathy, Nerve Injury, Neuropathic Pain, Post-Operative Pain, Stable Angina and Unspecified.

Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Overview

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Companies Involved in Therapeutics Development

Allergan Plc

Amgen Inc

Biohaven Pharmaceutical Holding Company Ltd

Eli Lilly and Company

Fortress Biotech Inc

Merck & Co Inc

Teva Pharmaceutical Industries Ltd

Vertex Pharmaceuticals Inc

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Drug Profiles

A-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AA-71-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AFAP-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-241689-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Atogepant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BHV-3500-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGRP-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erenumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8825-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rimegepant sulfate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CALCRL for Migraine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CGRP Receptor for Migraine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CGRP for Migraine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ubrogepant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Dormant Products

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Discontinued Products

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)-Product Development Milestones

Featured News & Press Releases

Jun 08, 2017: Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society

Jun 08, 2017: Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting

May 18, 2017: Amgen Submits Biologics License Application To The FDA For Erenumab

May 18, 2017: Heptares to Receive US$5 Million Milestone Payment from Teva

Nov 16, 2016: Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study

Sep 28, 2016: Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study

Sep 15, 2016: Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine

Sep 15, 2016: Novartis announces new positive data showing AMG 334 significantly reduces monthly migraine days in chronic migraine vs placebo

Sep 14, 2016: Amgen present erenumab at webcast call

Jun 08, 2016: Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine

Jun 19, 2015: Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine

May 15, 2015: Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine

May 11, 2015: Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Allergan Plc, H1 2017

Pipeline by Amgen Inc, H1 2017

Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2017

Pipeline by Eli Lilly and Company, H1 2017

Pipeline by Fortress Biotech Inc, H1 2017

Pipeline by Merck & Co Inc, H1 2017

Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Therapeutic Products under Development, Key Players in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Therapeutics, Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Pipeline Overview, Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Pipeline, Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Pipeline Assessment


Companies

Allergan Plc

Amgen Inc

Biohaven Pharmaceutical Holding Company Ltd

Eli Lilly and Company

Fortress Biotech Inc

Merck & Co Inc

Teva Pharmaceutical Industries Ltd

Vertex Pharmaceuticals Inc